Produits biochimiques et réactifs

<p>Portion of Influenza A</p>

<p>SB-616234-A is a benzodiazepine receptor ligand that has anxiolytic and antidepressant properties. It is a selective 5-HT7 receptor antagonist, which binds to the benzodiazepine site on the 5-HT7 receptor. SB-616234-A has been shown to have an antidepressant effect in animal models of depression. This drug also has anxiolytic effects, as it blocks the action of serotonin at the 5-HT1a receptor. The drug is orally active and does not cross the blood brain barrier.</p>

<p>Mouse monoclonal Cardiotin antibody</p>

<p>The CDH13 antibody is a glycoprotein that specifically targets autoantibodies. It is a monoclonal antibody that contains a cycloalkyl group and has been shown to have cytotoxic effects. This antibody can be used in various applications, including immunohistochemistry, flow cytometry, and Western blotting. The CDH13 antibody has been used in research studies to investigate the role of CDH13 in different biological processes, such as cell adhesion and migration. It has also been used in combination with other antibodies, such as anti-CD33 antibody or sorafenib, to enhance its therapeutic potential. The CDH13 antibody has shown promising results in preclinical studies, demonstrating its ability to induce hemolysis and necrosis factor-related apoptosis-inducing effects on target cells. With its wide range of applications and potential therapeutic benefits, the CDH13 antibody is an essential tool for researchers in the field of Life Sciences.</p>

<p>Purified recombinant TIMP2 protein (His tag)</p>

<p>Rabbit polyclonal ADH5 antibody</p>

<p>Rabbit polyclonal RAB3GAP1 antibody</p>

<p>Please enquire for more information about Ciprofibrate-d6 including the price, delivery time and more detailed product information at the technical inquiry form on this page</p>

<p>BIRG 613 BS is a high-purity drug substance that has been validated using chromatographic and spectroscopic methods. It is intended for the manufacture of nevirapine. The purity of BIRG 613 BS is determined by measuring its chemical composition, impurities, and other properties. The chromatographic method involves the application of a liquid solvent to a solid material in order to separate it into individual components. This process relies on the different rates at which substances will dissolve in the solvent or be absorbed by the stationary phase. The linearity of BIRG 613 BS was measured by finding its coefficient and comparing it to a standard curve created from known concentrations of nevirapine.</p>

<p>Ghrelin is a peptide hormone that is produced by the stomach and plays an important role in regulating appetite. Ghrelin stimulates hunger by activating the ghrelin receptor, which is found on cells throughout the body. The ghrelin receptor has been shown to be a G-protein coupled receptor (GPCR), which has seven transmembrane domains with intracellular loops that form a ligand binding pocket. Ghrelin binds to its receptor, leading to activation of the G protein and subsequent opening of ion channels. This leads to depolarization of the cell membrane, which creates an action potential that ultimately triggers neurotransmitter release from the neuron. Des-Gln14-Ghrelin (rat) is a synthetic analog of ghrelin that may be used as a research tool for studying ion channels or protein interactions.</p>

<p>CER6-2′R(d9) is a peptide that is a potent activator of the human vasopressin V2 receptor. It has been shown to selectively activate the V2 receptor in cells and animals, with no agonistic activity at other receptors. CER6-2′R(d9) is a highly purified peptide that can be used as a research tool for studying the structure and function of the vasopressin V2 receptor. The peptide binds to the extracellular domain of the receptor and stabilizes its conformation, which leads to increased receptor signaling.</p>

<p>Simetride is a pharmacological agent that belongs to the group of ligands. It binds to and activates ion channels, which are membrane-spanning proteins that allow ions to pass across the cell membrane. Simetride is a high-purity drug with a CAS number of 154-82-5. It has been used as an experimental tool in cell biology and biochemistry laboratories for over 30 years.</p>

<p>NAS-181 is a drug that inhibits the voltage-dependent calcium channels. It has been shown to be effective in reducing pain and inflammation from chronic headaches. NAS-181 is a non-selective antagonist of 5-HT1A and 5-HT1B receptors, which are both linked to the transmission of pain signals from the central nervous system. NAS-181 also affects neurotransmission by inhibiting glutamate release in the brain and monoamine neurotransmitters such as dopamine. This drug has been shown to inhibit neuronal activity in the mouse striatum, an area associated with motor control, cognition, and mood regulation.<br>br&gt;br&gt;<br>This drug is being developed for the treatment of migraine headaches.br&gt;br&gt;</p>

<p>CEP-28122 is a selective and potent small-molecule inhibitor, which is derived from chemical synthesis targeting receptor tyrosine kinases, specifically the fibroblast growth factor receptors (FGFRs). Its mode of action involves the competitive inhibition of ATP binding, thereby preventing the phosphorylation cascade necessary for signal transduction downstream of FGFRs. By inhibiting these pathways, CEP-28122 effectively impedes processes such as cell proliferation and angiogenesis, which are critical in various pathological conditions including cancer.</p>

<p>KPT-185 is a novel pro-apoptotic agent that selectively induces cell death in cancer cells resistant to platinum chemotherapy. KPT-185 kills tumor cells by inducing apoptosis through inhibition of the anti-apoptotic protein survivin. The drug also has minimal toxicity in mice, which may be due to its lack of effect on energy metabolism or transcriptional regulation. In addition, KPT-185 has been shown to have minimal toxicity in leukemic mice and does not cause significant changes in mouse tumor size or weight, indicating that it is well tolerated by normal tissues.</p>

<p>Furosemide is an organic solvent that is used as a salt of furosemide sodium. It has been shown to have strong absorption in the UV range, which can be used for cellular and environmental pollution. Furosemide is also a natriuretic drug that is used to decrease blood pressure and to prevent and treat heart failure. Furosemide may be given orally or intravenously, which will lead to an increase in plasma albumin levels. This drug also binds to surfactant proteins, which are necessary for maintaining the stability of lung surfactant and preventing it from collapsing on itself. Furosemide inhibits the formation of calcium carbonate precipitates by chelating magnesium ions from solution. The drug also has a hydrodynamic effect on electrolytes such as sodium, potassium, and chloride ions. This leads to increased urinary excretion of these ions and a reduction in their concentrations in the blood plasma.<br>Furosemide is often formulated with other</p>

<p>Etamiphyllin is a sesquiterpene lactone that has been used as an analog of vitamin C. It is a pharmaceutical preparation used in the treatment of symptoms associated with autoimmune diseases and other inflammatory conditions. Etamiphyllin is administered intravenously, orally, or topically, depending on the severity of the condition. Etamiphyllin is also detected in vitro by measuring fatty acid-derived hydroxyl ions generated during its metabolism. These ions are measured using a particle detector and then quantified using gas chromatography-mass spectrometry (GC-MS). Etamiphyllin can be detected in urine samples for up to five hours after administration.</p>

<p>L-745870 Hydrochloride is a selective dopamine D4 receptor antagonist, which is synthesized as a research compound for neuroscientific studies. This product originates from medicinal chemistry efforts aimed at understanding the role of dopamine receptors in brain function and pathology. Its mode of action involves the competitive inhibition of the dopamine D4 receptor, a subtype of the dopamine receptor family, which plays a significant role in modulating neuronal signaling pathways associated with cognition, emotion, and potential behavioral disorders.</p>

<p>Berkeleylactone F is an analog of ceftiofur, which has been found to have potent anticancer activity. It selectively inhibits kinases that are involved in tumor growth and survival pathways, leading to apoptosis (cell death) of cancer cells. Berkeleylactone F has been shown to be effective against a variety of human cancer cell lines, including those resistant to other kinase inhibitors. This compound also shows promising activity against Chinese hamster ovary cells, making it a potential treatment for various types of cancer. Additionally, Berkeleylactone F has been found in urine samples, suggesting that it may have potential as a diagnostic tool for detecting certain cancers.</p>

<p>KU 59403 is a potent inhibitor that functions as an anti-proliferative agent, targeting specific biochemical pathways. Developed through chemical synthesis, it primarily acts as an inhibitor of DNA-dependent protein kinase (DNA-PK). This kinase is integral to the non-homologous end joining (NHEJ) pathway, responsible for repairing double-strand breaks in DNA.</p>

<p>Papaveroxine is a medicinal compound that has been found to have potential anticancer properties. It is an analog of elastin kinase, which plays a role in the regulation of cell growth and division. Papaveroxine has been isolated from urine samples and has shown promising results as an inhibitor of cancer cell growth and proliferation. Studies have shown that this compound induces apoptosis, or programmed cell death, in human cancer cells by inhibiting protein kinases that are involved in tumor growth. Furthermore, papaveroxine has been found to be effective against a variety of cancers, including breast, lung, and prostate cancer. This makes it a promising candidate for the development of new cancer treatments and inhibitors.</p>

<p>PD 168077 is a dopamine uptake inhibitor that is used to study the function of dopamine in the brain. It selectively inhibits the uptake of dopamine into synaptic vesicles and blocks the binding of dopamine to its receptor, leading to an increased amount of dopamine in the synapse. PD 168077 has been shown to be effective against autoimmune diseases such as multiple sclerosis, but also against cancerous cells. Studies have shown that PD 168077 inhibits protein synthesis in tumor cell cultures and inhibits tumor growth in mice.</p>

<p>N-1,3-Benzodioxol-5-yl-1-(4-nitrobenzyl)-1H-imidazole-4-carboxamide is a high purity research tool. It can be used in the study of receptor and ligand interactions as well as ion channels. This product is also used for Cell Biology and Antibodies.</p>

<p>TCS OX2 29 is a vasoactive intestinal peptide (VIP) receptor agonist that has been shown to have analgesic effects in rats. TCS OX2 29 is an excitatory neurotransmitter, which may be due to its ability to stimulate the release of glutamate and increase the activity of postsynaptic receptors. TCS OX2 29 also has a significant interaction with antinociceptive drugs such as morphine, which may be due to its ability to activate opioid receptors. Patch-clamp experiments on tegmental neurons have shown that TCS OX2 29 increases the frequency of spontaneous action potentials in these cells. It also induces locomotor activity in mice and pain hypersensitivity in rats. TCS OX2 29 has been used as an experimental model for symptoms associated with Parkinson’s disease, such as akinesia and muscle rigidity.</p>

<p>Inhibitor of Mdm2-p53 interaction</p>

<p>Glycolate is a chemical compound that is found in the leaves of beans and other plants. Glycolate is oxidized by glycolic acid oxidase (GAO) to form glyoxylic acid, which is then converted to glyoxylate by GAO. Glyoxylate can be converted to glycine, an amino acid that helps with protein synthesis, or it can be converted to oxalate, a toxin. Glycolic acid oxidase inhibitor 1 (GAOI-1) prevents the oxidation of glycolate into glyoxylic acid by stopping the cycle of GAO. GAOI-1 binds to one of the intermediate products in this cycle and inhibits its activity. It has been shown to reduce leaf tissue damage caused by high levels of photosynthesis.</p>

<p>Vercirnon is a small molecule antagonist, which is derived from synthetic chemical processes with a specific mode of action targeting the CCR9 receptor. This receptor is a chemokine receptor involved in the migration of inflammatory cells to the gastrointestinal tract. By inhibiting the CCR9 receptor, Vercirnon aims to reduce the recruitment of lymphocytes to sites of inflammation, thereby dampening the inflammatory response.</p>

<p>ETP-46321 is an imidazopyrazine that inhibits the activity of the enzyme phosphatase 2A, which is involved in a number of signaling pathways. It has been shown to activate IL-17a, and inhibit tumor growth in mice. ETP-46321 also has pharmacokinetic properties that are suited for oral administration. The drug binds to the catalytic subunit of protein phosphatase 2A (PP2Ac) and prevents it from dephosphorylating its substrate, thereby inhibiting its enzymatic activity. This inhibition leads to increased levels of activated PP2Ac, which in turn leads to the activation and proliferation of cells. ETP-46321 has shown efficacy against cancer cells in vitro and can be used as an immunosuppressant for autoimmune diseases due to its ability to inhibit IL-17a production by T cells.</p>

<p>XMD8-87 is a cancer drug under development by Novartis that inhibits the growth of tumor cells by blocking the activity of kinases. XMD8-87 is selective for SRC family kinases and has been shown to inhibit the growth of tumor cells in vitro and in vivo. The drug has also been shown to have an effect on other types of cancer cells, including lung, colon, prostate, and breast cancers. XMD8-87 binds to a region targeted by many drugs that are currently used for cancer treatment, including dasatinib and imatinib. This may make it possible to use XMD8-87 as a substitute or complementary treatment option.</p>

<p>3,4-Dihydroxy-5-nitrophenyl)(2-fluorophenyl)methanone (NSC 663128) is a potent and selective growth factor that binds to the dopamine receptor. It has been shown to inhibit protein tyrosine phosphorylation and cell proliferation in vitro. This compound has also been shown to protect against neurotoxicity induced by methamphetamine in rats. NSC 663128 has also demonstrated an anti-cancer effect on human cancer cells, including leukemia cells and breast cancer cells. The mechanism of this effect may be due to inhibition of catechol-o-methyltransferase, epidermal growth factor receptor, or other cellular targets.</p>

<p>GSK-843 is a drug that interacts with the kinase activity of the protein kinase A (PKA), which is an enzyme that phosphorylates proteins. GSK-843 also modulates the PKA and protein kinase C (PKC) activities, which are enzymes involved in cell signaling. Treatment with GSK-843 led to a significant reduction in cell viability and necrotic cell death, as well as reduced hepatic steatosis in animals. This drug has been shown to suppress TNF-α, an inflammatory cytokine, and fatty acid synthase, an enzyme involved in lipid metabolism, which may contribute to its anticancer activity.</p>

<p>BIRT 377 is a humanized monoclonal antibody with specificity for the inflammatory molecule MCP-1. It is being developed as a therapy for inflammatory bowel disease, which is characterized by chronic inflammation of the gastrointestinal tract. BIRT 377 binds to MCP-1 and blocks its interaction with the receptor CCR2 on the surface of cells in the gastrointestinal tract. This prevents inflammatory responses that are responsible for tissue damage and ulceration. BIRT 377 has been shown to be effective in animal models of inflammatory bowel disease, and clinical studies are underway in humans.</p>

<p>SID 26681509 is an enzyme inhibitor that inhibits toll-like receptor (TLR) signaling pathways. TLRs are a family of proteins that act as pattern recognition receptors for the detection of microbial or viral components. SID 26681509 has been shown to inhibit HIV infection in primary cells and to induce autophagy, which may be due to its ability to inhibit methyl transferase activity. It also has been shown to reduce inflammation in mouse models of autoimmune diseases by inhibiting chemoattractant protein expression.</p>

<p>3-(4-{4-Aminofuro[2,3-d]pyrimidin-5-yl}phenyl)-1-[2-fluoro-5-(trifluoromethyl)phenyl]urea is an inhibitor of ion channels. It is a ligand that binds to the receptor site on ion channels and blocks them. The protein interactions of 3-(4-{4-aminofuro[2,3-d]pyrimidin-5-yl}phenyl)-1-[2-fluoro-5-(trifluoromethyl)phenyl]urea are not yet known. This drug has been shown to have a high purity, often greater than 99%. The CAS number for this drug is 501693-48-.</p>

<p>Candesartan-d5 is a peptide that binds to the angiotensin II receptor, which is found in many tissues including the vasculature of the lungs and kidneys. This drug blocks the binding of angiotensin II to its receptor, thereby inhibiting vasoconstriction, increasing urine volume and decreasing blood pressure. Candesartan-d5 has been shown to have high purity with a purity greater than 99%. It is used in research as an activator for antibodies, as well as a ligand or receptor for pharmacological studies.</p>

<p>Purified recombinant ULBP1 protein (His tag)</p>

<p>Purified recombinant BCCIP protein (His tag)</p>

<p>Purified Polyclonal MYBPC2 antibody</p>

<p>Rabbit polyclonal GBP4 antibody</p>

<p>Purified recombinant GOSR2 protein (His tag)</p>

<p>Purified Polyclonal TCEB3C antibody</p>

<p>The SP1 antibody is a highly specialized product in the field of Life Sciences. It belongs to the category of anti-CD20 antibodies and is used for various research purposes. This antibody specifically targets and binds to the CD20 protein, which is expressed on the surface of certain cells, including B lymphocytes.</p>

<p>Mouse monoclonal CNDP1 antibody</p>

<p>Mouse macrophage antibody was raised in rabbit using murine macrophages as the immunogen.</p>

<p>The SOX2 antibody is a nuclear antibody that is commonly found in human serum. It is often used in research related to interferon-gamma (IFN-gamma) and other aspects of the immune system. This monoclonal antibody specifically targets the SOX2 protein, which plays a crucial role in various cellular processes. It has been shown to interact with actin filaments, leading to changes in cell morphology and function. Additionally, this antibody has cytotoxic properties and can be used to selectively target and destroy activated cells. With its high specificity and effectiveness, the SOX2 antibody is widely used in life sciences research and holds great potential for therapeutic applications.</p>

<p>Mouse monoclonal TBCB antibody</p>

<p>LOC285033 antibody was raised using the N terminal of LOC285033 corresponding to a region with amino acids VIKEGAVCGIARPKTSRVNSSQDQIQVASENTHSGSLHQRPASGARLPAS</p>

<p>Rabbit polyclonal RAB3B antibody</p>

<p>Oasl1 antibody was raised in rabbit using the C terminal of Oasl1 as the immunogen</p>

<p>The CNP antibody is a highly specialized antibody used in the field of Life Sciences. It specifically targets insulin and adipocyte-related proteins, making it an invaluable tool for researchers studying these areas. This polyclonal antibody has been developed to detect and measure the levels of superoxide, fatty acids, interferon, and e-cadherin expression in various samples. Its high specificity and sensitivity make it ideal for use in experiments investigating the role of insulin in adipose tissue and its effects on other cellular processes. Whether you are studying metabolic disorders or exploring new therapeutic approaches, the CNP antibody can provide valuable insights into the intricate mechanisms underlying these conditions. Trust this reliable antibody to deliver accurate and reproducible results for your research needs.</p>